PHARMACODYNAMIC EQUIVALENCE OF USING 3-MONTH AND 28-DAY SUSTAINED-RELEASE DECAPEPTYL DEPOT FORMULATIONS IN PATIENTS WITH ADVANCED PROSTATE CANCER

PHARMACODYNAMIC EQUIVALENCE OF USING 3-MONTH AND 28-DAY SUSTAINED-RELEASE DECAPEPTYL DEPOT FORMULATIONS IN PATIENTS WITH ADVANCED PROSTATE CANCER

Show other versions (1)

<p><strong>Objective</strong>: to evaluate the pharmacodynamic equivalence of 3-month and 28-day formulations of tryptoreline, a sustained-release luteininghormone (LH)-releasing hormone analogue.</p><p><strong>Subjects and methods</strong>. The patients who...

Full description

Bibliographic Details
Main Authors:	P. Teillac, C. F. Heyns, A. V. Kaisary, O. Bouchot, J. Blumberg
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkourologiâ
Online Access:	http://oncourology.abvpress.ru/index.php/oncur/article/view/209

Similar Items

PHARMACODYNAMIC EQUIVALENCE OF USING 3-MONTH AND 28-DAY SUSTAINED-RELEASE DECAPEPTYL DEPOT FORMULATIONS IN PATIENTS WITH ADVANCED PROSTATE CANCER
by: P. Teillac, et al.
Published: (2014-07-01)

Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
by: Rajni Sethi, et al.
Published: (2009-06-01)

Follikeldynamik und korrespondierende Hormonkonzentration beim Rind unter dem Einfluss eines GnRH-Agonisten in Depotformulierung (Decapeptyl Depot)
by: Bellmann, Annett
Published: (2004)

Follikeldynamik und korrespondierende Hormonkonzentration beim Rind unter dem Einfluss eines GnRH-Agonisten in Depotformulierung (Decapeptyl Depot)
by: Bellmann, Annett
Published: (2004)

The Effects of Decapeptyl on Morphology and Quantity of Neurons in Hippocampus of Mice Treated with Cyclophosphamide
by: Afsaneh Niakani, et al.
Published: (2012-05-01)

Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation
by: Tunn UW, et al.
Published: (2013-04-01)

ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER
by: M. I. Volkova
Published: (2014-07-01)

ROLE OF LEUPRORELINE ACETATE DEPOT (LUCRIN DEPOT®) FORMULATIONS IN THE TREATMENT OF PROSTATE CANCER
by: M. I. Volkova
Published: (2014-07-01)

Pharmacodynamics, toxicology and toxicokinetics of ropivacaine oil delivery depot
by: Cao, Y.-X, et al.
Published: (2022)

A fluorescence-based assay for octreotide in kinetic release from depot formulations
by: Luiz Henrique Guerreiro, et al.
Published: (2012-01-01)

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
by: Youwei Bi, et al.
Published: (2018-04-01)

Midazolam-sirupus, formulation and pharmacodynamic efficacy
by: K. Goracinova, et al.
Published: (2002-04-01)

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation
by: Wex J, et al.
Published: (2013-06-01)

New and alternative approaches to the assessment of pharmacokinetic and pharmacodynamic equivalence
by: Ozdin, Deniz
Published: (2021)

Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer
by: L. M. Rapoport, et al.
Published: (2014-12-01)

Use of Buserelin depot, a gonadotropin-releasing hormone agonist, in the treatment of prostate cancer
by: L. M. Rapoport, et al.
Published: (2014-12-01)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
by: Min Jin Jeon, et al.
Published: (2021-09-01)

Design of a depot formulation for disulfiram
by: Mia, Fatema
Published: (2017)

An assessment of the clinical equivalence of valproate chrono and extended release divalproex formulations
by: Rajesh B, et al.
Published: (2007-01-01)

Population pharmacokinetic/pharmacodynamic (PK/PD) modeling of depot testosterone cypionate in healthy male subjects
by: Bi, Youwei
Published: (2016)

Buserelin-depot in the treatment of prostate cancer
by: G. P. Kolesnikov
Published: (2015-09-01)

Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort
by: Phillips JM, et al.
Published: (2011-07-01)

Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder
by: Michele Basile, et al.
Published: (2021-07-01)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
by: Michael Kukulka, et al.
Published: (2016-11-01)

Crude protein equivalence value of a multi-enzyme product for 28- and 42-day-old broilers
by: A Malakzadegan, et al.
Published: (2012-12-01)

Amyloid as a depot for the formulation of long-acting drugs.
by: Samir K Maji, et al.
Published: (2008-02-01)

Leveraging Mathematical Modeling to Quantify Pharmacokinetic and Pharmacodynamic Pathways: Equivalent Dose Metric
by: Matthew T. McKenna, et al.
Published: (2019-05-01)

Pharmacokinetic/pharmacodynamic modeling/simulation and novel gastric retention formulation
by: Kwon, Hyojong
Published: (2012)

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
by: Alberts, M., et al.
Published: (2022)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
by: Sihem Ait-Oudhia, et al.
Published: (2014-03-01)

Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of Schizophrenia
by: Ranković Anica, et al.
Published: (2018-03-01)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
by: Kim D, et al.
Published: (2019-09-01)

Pharmacodynamic equivalence study of two preparations of eye drops, containing dorzolamide in healthy volunteers
by: Gatchev Emil M., et al.
Published: (2016-01-01)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
by: Wang SM, et al.
Published: (2014-08-01)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
by: Carpiniello B, et al.
Published: (2016-05-01)

Effects of formulation types on pharmacodynamics of warfarin in patients with cerebral infarction and dysphagia
by: Kim YJ, et al.
Published: (2019-03-01)

Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen
by: Shin D, et al.
Published: (2017-01-01)

Formulation, optimization, and pharmacodynamic evaluation of chitosan/phospholipid/β-cyclodextrin microspheres
by: Shan L, et al.
Published: (2016-01-01)

Injectable Lipid-Based Depot Formulations: Where Do We Stand?
by: Lisa Rahnfeld, et al.
Published: (2020-06-01)

A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients
by: Tunn Ulf W
Published: (2011-07-01)